Q-omics provides the consensus-scored WDR17 profile across patient tissues and cancer cell-line models. WDR17 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WDR17 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, WDR17 RNA expression shows 19,017 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where WDR17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR17 survival associations across molecular data types. WDR17 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR17 RNA expression–survival associations across cancer types. High WDR17 expression shows unfavorable associations in UCEC and LUSC, but favorable associations in KIRC, BRCA, PAAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WDR17 RNA expression.
This table summarizes WDR17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR17 shows lower tumor expression in THCA, COAD, LUSC, BLCA, LUAD and LIHC. The THCA box plot shows higher WDR17 RNA expression in normal versus tumor tissue (log2 FC = −1.230, t-test p < 0.001).
This table shows molecular features associated with WDR17 in patient tissues and cancer cell lines. In patient samples, WDR17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
